Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT07426952 | Weight Management After Cancer for Survivors in Rural Communities(WeCan-Rural) | recruiting | N/A | 40 | Duke UniversityOTHER | 1 |
| Aug 13, 2026 |
| clinicaltrials |
| NCT07762885 | Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving Surgery | recruiting | Phase 3 | 636 | Fudan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07762924 | Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving Surgery | recruiting | Phase 2 | 234 | Fudan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04768426 | Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | recruiting | Phase 2 | 40 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05072314 | Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial(LOLIPOP) | recruiting | Phase 3 | 4,300 | Monash UniversityOTHER | 4 | Aug 12, 2026 | clinicaltrials |
| NCT05145244 | Copenhagen Master Observational Trial(C-MOT) | recruiting | — | 2,400 | Rigshospitalet, DenmarkOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05304962 | FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer | recruiting | Phase 1 | 64 | Regor Pharmaceuticals Inc.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06263543 | Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC(SERIES) | recruiting | Phase 2 | 75 | Reshma L. Mahtani, D.O.OTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06525766 | Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer | recruiting | Phase 2 | 35 | Mayo ClinicOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06885203 | Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI) | recruiting | N/A | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07300995 | Behavioral Pain Intervention for Older Cancer Patients | recruiting | N/A | 168 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07502820 | The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancER(POWER) | recruiting | Phase 3 | 1,100 | Karolinska InstitutetOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07752238 | Diagnostic Prediction Model for De Novo Metastatic Breast Cancer | recruiting | — | 925 | Markusovszky University Teaching Hospital os County VasOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760012 | 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors(SORB-PET) | recruiting | N/A | 50 | Peking University Third HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03408353 | Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study | recruiting | — | 10,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04517266 | Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer | recruiting | N/A | 214 | Ruijin HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06715020 | Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging | recruiting | N/A | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07358377 | A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer | recruiting | Phase 1 | 15 | Atridia Pty Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07602907 | Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study | recruiting | Phase 2 | 73 | Zhejiang Cancer HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05111561 | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05694559 | Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics | recruiting | N/A | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05893966 | Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer(BOOST-HER2) | recruiting | — | 400 | Samsung Medical CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06092892 | IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases | recruiting | Phase 2 | 45 | Alice ChungOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06127797 | Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue | recruiting | — | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06930859 | Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia(ELEGANCE) | recruiting | — | 2,766 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07044310 | 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss | recruiting | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07304934 | A Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast Cancer(PRO-TuFEst-LN) | recruiting | — | 400 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07482384 | Supporting Health Including Endocrine Treatment for Long Duration(SHIELD) | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07741968 | A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer | recruiting | N/A | 126 | City of Hope Medical CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06638307 | A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | recruiting | Phase 1 | 240 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT07140172 | Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery(OPBC-10/ NOAX) | recruiting | N/A | 1,060 | University Hospital, Basel, SwitzerlandOTHER | 11 | Aug 7, 2026 | clinicaltrials |
| NCT07242352 | Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC(ADAPTela) | recruiting | Phase 3 | 1,520 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02102165 | AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.(AURORA) | recruiting | N/A | 1,000 | Jules Bordet InstituteOTHER | 10 | Aug 6, 2026 | clinicaltrials |
| NCT05232916 | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects(FLAMINGO-01) | recruiting | Phase 3 | 2,250 | Greenwich LifeSciences, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT06129747 | Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast | recruiting | Phase 2 | 55 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06176261 | DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | recruiting | Phase 2 | 58 | Nancy Lin, MDOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06439693 | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06586047 | Breast Cancer PSMA PET | recruiting | Early Phase 1 | 30 | Ahmad ShariftabriziOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07512271 | Generative AI Patient Education Module for Breast Oncology | recruiting | N/A | 35 | University of California, San FranciscoOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05318469 | Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 34 | Yuan YuanOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05507879 | TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer | recruiting | — | 200 | Mayo ClinicOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | recruiting | Phase 3 | 1,295 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 5, 2026 | clinicaltrials |
| NCT06106477 | Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer | recruiting | N/A | 20 | Medical College of WisconsinOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06469606 | Study on Female Patients' Mammographic Texture Features(COMPRESS) | recruiting | N/A | 200 | Tampere University HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06658912 | Planning Grant for TOPS for Breast Cancer Survivors | recruiting | N/A | 25 | Duke UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability(DEFEND) | recruiting | N/A | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 13, 2026source: clinicaltrials